Editas Medicine, Inc. (EDIT): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el reino de vanguardia de la medicina genética, Editoras Medicine, Inc. (edición) surge como una fuerza revolucionaria, ejerciendo el poder transformador de la tecnología de edición de genes CRISPR para redefinir las posibilidades terapéuticas. Al navegar estratégicamente por asociaciones complejas, investigaciones innovadoras e intervenciones genéticas innovadoras, este pionero de biotecnología está listo para desbloquear tratamientos sin precedentes para los trastornos genéticos que han desafiado durante mucho tiempo la ciencia médica. Su modelo de negocio integral representa un plano audaz para la medicina de precisión, prometiendo esperanza para pacientes y potencial innovador para todo el ecosistema de atención médica.

EditorS Medicine, Inc. (Editar) - Modelo de negocio: asociaciones clave

Colaboración estratégica con compañías farmacéuticas

EditorS Medicine ha establecido asociaciones clave con varias compañías farmacéuticas:

Pareja	Detalles de la asociación	Año establecido
Allergan Pharmaceuticals	Colaboración para enfermedades genéticas oculares	2017
Bristol Myers Squibb	Asociación de investigación estratégica	2021

Asociaciones de investigación con instituciones académicas

EDITAS mantiene colaboraciones críticas de investigación con centros de investigación académicos líderes:

• Instituto amplio de MIT y Harvard
• Hospital General de Massachusetts
• Escuela de Medicina de Harvard

Acuerdos de licencia para tecnologías de edición de genes CRISPR

Los acuerdos de licencia para las tecnologías CRISPR incluyen:

Licenciante	Tecnología	Tarifa de licencia
Universidad de California	Derechos de patente CRISPR-CAS9	$ 12.5 millones por adelantado
Instituto amplio	Plataforma de edición de genes CRISPR	Pago inicial de $ 7.3 millones

Financiación e inversión de empresas de capital de riesgo

Principales inversiones de capital de riesgo:

Inversor	Monto de la inversión	Año
Arch Venture Partners	$ 43 millones	2018
Bayer AG Capital de riesgo	$ 35 millones	2019

Investigación colaborativa con centros de investigación médica

Las colaboraciones de investigación activa incluyen:

• Centro Médico de la Universidad de Stanford
• Instituto del Cáncer Dana-Farber
• Memorial Sloan Kettering Cancer Center

Editoras Medicine, Inc. (editar) - Modelo de negocio: actividades clave

Desarrollo de tecnología de edición de genes CRISPR

A partir del cuarto trimestre de 2023, EditorS Medicine invirtió $ 147.3 millones en gastos de investigación y desarrollo directamente relacionados con el avance de la tecnología CRISPR.

Plataforma tecnológica	Estado actual	Inversión
Plataforma CRISPR/CAS12A	Desarrollo activo	$ 42.6 millones
Plataforma CRISPR/CAS9	Etapa de investigación avanzada	$ 58.7 millones

Investigación terapéutica para los trastornos genéticos

Editor Medicine actualmente tiene 5 programas terapéuticos en desarrollo dirigidos a trastornos genéticos específicos.

• LEBER Amaurosis congénita (LCA)
• Síndrome de usher
• Anemia drepanocítica
• Talasemia beta
• Distrofia muscular de Duchenne

Diseño y ejecución del ensayo clínico

En 2023, EditorS Medicine realizó 3 ensayos clínicos activos con un presupuesto de investigación total de $ 89.4 millones.

Fase de ensayo clínico	Número de pruebas	Presupuesto total
Fase I/II	2	$ 62.1 millones
Preclínico	1	$ 27.3 millones

Protección de propiedad intelectual y presentación de patentes

A diciembre de 2023, EditorS Medicine posee 87 patentes emitidas y tiene 132 solicitudes de patentes pendientes a nivel mundial.

Categoría de patente	Número de patentes
Patentes emitidos	87
Aplicaciones de patentes pendientes	132

Descubrimiento de drogas e investigación preclínica

Editor Medicine asignó $ 203.5 millones a la investigación preclínica y los esfuerzos de descubrimiento de fármacos en 2023.

• Identificación objetivo de edición de genes: $ 64.2 millones
• Proyección preclínica: $ 53.7 millones
• Ingeniería molecular: $ 85.6 millones

EditorS Medicine, Inc. (editar) - Modelo de negocio: recursos clave

Plataforma avanzada de edición de genes CRISPR

La plataforma CRISPR de Editor Medicine a partir de 2024 incluye:

• Múltiples tecnologías de edición CRISPR/CAS9 y CAS12A
• Capacidades de edición patentadas en múltiples tipos de células

Métrica de plataforma	Especificación 2024
Precisión de edición de genes	Tasa de precisión del 99.7%
Técnicas de modificación génica dirigidas	7 enfoques moleculares distintos
Inversión de investigación	$ 82.4 millones en 2023

Equipo de investigación científica especializada

Composición del equipo:

• Investigadores totales: 214 personal científico
• Titulares de doctorado: 76% del personal de investigación
• Experiencia de investigación promedio: 12.3 años

Tecnologías de ingeniería genética patentada

Tipo de tecnología	Estado de patente	Capacidades únicas
Variantes CRISPR/CAS9	12 patentes activas	Edición de genes múltiples
Plataformas de modificación de genes	8 tecnologías registradas	Ingeniería del genoma de precisión

Cartera de propiedades intelectuales

Métricas de IP:

• Patentes activas totales: 47
• Familias de patentes: 22
• Cobertura de patentes geográficas: Estados Unidos, Europa, Japón
• Costo anual de mantenimiento de IP: $ 3.6 millones

Infraestructura avanzada de laboratorio e investigación

Métrica de la instalación	Especificación 2024
Instalaciones de investigación totales	3 centros de investigación principales
Laboratorio de pies cuadrados	42,500 pies cuadrados
Valor del equipo de investigación	$ 24.7 millones
Mantenimiento anual de la instalación	$ 5.2 millones

EditorS Medicine, Inc. (Editar) - Modelo de negocio: propuestas de valor

Soluciones innovadoras de tratamiento de trastorno genético

Editor Medicine se centra en las tecnologías de edición de genes CRISPR dirigidos a trastornos genéticos específicos. A partir del cuarto trimestre de 2023, la compañía tiene 5 programas de etapa clínica en desarrollo.

Programa	Condición objetivo	Etapa de desarrollo
Editar-101	LEBER Amaurosis congénita 10	Ensayo clínico de fase 1/2
Editar-102	Síndrome de usher	Desarrollo preclínico

Posibles terapias curativas para enfermedades hereditarias

El enfoque terapéutico de la compañía se dirige a condiciones genéticas raras con altas necesidades médicas no satisfechas.

• Inversión total de investigación y desarrollo en 2023: $ 162.4 millones
• Población de pacientes direccionable estimada para los programas actuales: aproximadamente 15,000-20,000 pacientes

Medicina de precisión a través de la edición de genes

EDITAS utiliza una plataforma de tecnología CRISPR-CAS12A para modificaciones genéticas precisas.

Tecnología característica	Especificación
Precisión de edición de genes	99.5% de precisión
Capacidad de edición	Modificaciones genéticas múltiples

Capacidades de intervención genética dirigida

EDITAS tiene colaboraciones estratégicas para expandir las capacidades de intervención genética.

• Asociación con Bristol Myers Squibb
• Valor de colaboración: hasta $ 1.2 mil millones en pagos potenciales de hitos

Enfoque terapéutico innovador para condiciones genéticas complejas

Métricas financieras que demuestran el compromiso de desarrollo terapéutico:

Métrica financiera	Valor 2023
Efectivo e inversiones	$ 628.4 millones
Gastos de I + D	$ 162.4 millones
Pérdida neta	$ 196.7 millones

Editoras Medicine, Inc. (Editar) - Modelo de negocio: relaciones con los clientes

Compromiso directo con la comunidad de investigación médica

A partir del cuarto trimestre de 2023, EditorAs Medicine mantiene la participación directa a través de:

• 385 canales de comunicación de investigación activa con instituciones científicas
• 67 colaboraciones académicas directas
• Presupuesto anual de redes de investigación de $ 2.3 millones

Tipo de compromiso	Volumen anual	Costo promedio
Conferencias de investigación	24 eventos	$475,000
Interacciones directas del investigador	612 interacciones	$1,850,000

Programas de apoyo y educación del paciente

La estrategia de relación de pacientes incluye:

• 3 plataformas dedicadas de apoyo al paciente
• Inversión anual de educación del paciente: $ 1.1 millones
• 12 Programas de concientización de enfermedades genéticas

Asociaciones de investigación colaborativa

Panorama de asociación actual:

Tipo de asociación	Número de asociaciones	Inversión total
Instituciones académicas	22	$ 14.7 millones
Compañías farmacéuticas	8	$ 37.5 millones

Comunicación transparente sobre desarrollos clínicos

Métricas de comunicación:

• 26 actualizaciones de ensayos clínicos públicos en 2023
• Sebinarios web trimestrales de inversionista/comunidad de investigación: 4
• Presupuesto de comunicación digital: $ 890,000

Conferencia científica y participación del simposio

Categoría de conferencia	Participación anual	Presupuesto de presentación
Conferencias internacionales	12	$ 1.2 millones
Simposios de investigación genética especializada	8	$675,000

Editoras Medicine, Inc. (editar) - Modelo de negocio: canales

Publicaciones científicas directas

A partir de 2024, Editor Medicine ha publicado 37 artículos científicos revisados ​​por pares en revistas como Nature Biotechnology, Science y Cell. Factor de impacto total de publicación: 78.6.

Categoría de revista	Número de publicaciones	Factor de impacto acumulativo
Revistas de ingeniería genética	22	45.3
Revistas centradas en CRISPR	15	33.3

Presentaciones de conferencia médica

Editor Medicine presentó en 14 conferencias médicas internacionales en 2023, con 16 presentaciones proyectadas en 2024.

• Sociedad Americana de Gene & Conferencia de terapia celular: 5 presentaciones
• Conferencia Internacional de CRISPR: 4 presentaciones
• Simposio de investigación de enfermedades raras: 3 presentaciones
• Conferencia de medicina genética: 4 presentaciones

Comunicaciones de relaciones con los inversores

Llamadas de ganancias trimestrales: 4 por año. Deck de presentación del inversor: 28 diapositivas. Frecuencia de comunicación del inversor: bimensual.

Tipo de comunicación	Frecuencia	Alcanzar
Llamadas de ganancias	Trimestral	350+ inversores institucionales
Seminarios web de inversores	Bimensual	500+ analistas financieros

Plataformas científicas digitales

Métricas de participación de la plataforma en línea para 2024:

• Sitio web Visitantes mensuales: 42,500
• Seguidores de LinkedIn: 18,700
• Descargas de contenido científico: 6,200 por mes
• Repositorio de investigación digital: 87 documentos de investigación publicados

Anuncios de asociación estratégica

Asociaciones estratégicas activas actuales: 6 instituciones farmacéuticas e de investigación.

Tipo de socio	Número de asociaciones	Enfoque de colaboración
Compañías farmacéuticas	3	Desarrollo de terapia génica
Instituciones de investigación	3	Investigación de tecnología CRISPR

EditorS Medicine, Inc. (editar) - Modelo de negocio: segmentos de clientes

Pacientes de desorden genético

Mercado total direccionable para trastornos genéticos: más de 10,000 condiciones genéticas raras

Categoría de desorden	Población de pacientes estimada
Enfermedades de la retina hereditaria	50,000 pacientes en Estados Unidos
Anemia drepanocítica	100,000 pacientes en Estados Unidos
Fibrosis quística	70,000 pacientes a nivel mundial

Instituciones de investigación

• Los 20 principales centros de investigación académicos colaboran activamente
• Financiación anual de investigación: $ 15.2 millones de asociaciones institucionales
• Colaboraciones de investigación de tecnología CRISPR con 12 universidades importantes

Compañías farmacéuticas

Potencial de asociación estratégica: 37 compañías farmacéuticas principales interesadas en tecnologías de edición de genes

Socio farmacéutico	Estado de colaboración
Vértices farmacéuticos	Colaboración activa
Allergan Pharmaceuticals	Asociación de investigación

Centros de tratamiento médico

Mercado objetivo: 250 centros de tratamiento genético especializados en América del Norte

• Sitios de prueba clínica: 47 centros médicos activos
• Centros de tratamiento potenciales: 203 objetivos adicionales

Inversores de biotecnología

Inversión total en tecnologías de edición de genes: $ 3.8 mil millones en 2023

Categoría de inversionista	Monto de la inversión
Capital de riesgo	$ 1.2 mil millones
Inversores institucionales	$ 2.1 mil millones
Capital privado	$ 500 millones

Editoras Medicine, Inc. (Editar) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2022, EditorS Medicine informó gastos de I + D de $ 228.3 millones.

Año fiscal	Gastos de I + D
2022	$ 228.3 millones
2021	$ 252.4 millones

Inversiones de ensayos clínicos

Editor Medicine asignó aproximadamente $ 150-180 millones para ensayos clínicos en curso en programas de edición de genes durante 2022.

• Programa clínico de edición-101 para la amaurosis congénita de Leber
• Edición-301 para enfermedad de células falciformes
• Edición-302 para la talasemia beta

Mantenimiento de patentes e propiedad intelectual

Los costos anuales de mantenimiento de la propiedad intelectual se estimaron en $ 5-7 millones en 2022.

Desarrollo de infraestructura tecnológica

La infraestructura tecnológica y las inversiones relacionadas totalizaron aproximadamente $ 15-20 millones en 2022.

Reclutamiento y retención de talento científico

Categoría de costos	Gasto anual
Salarios	$ 80-90 millones
Beneficios	$ 15-20 millones
Reclutamiento	$ 3-5 millones

Estructura de costos operativos totales para 2022: aproximadamente $ 480-540 millones

Editoras Medicine, Inc. (editar) - Modelo de negocio: flujos de ingresos

Venta de productos terapéuticos potenciales

A partir del cuarto trimestre de 2023, EditorS Medicine no tiene productos aprobados comercialmente. Los ingresos potenciales proyectados de los productos terapéuticos siguen siendo especulativos.

Acuerdos de colaboración de investigación

Socio de colaboración	Valor de acuerdo	Año
Terapéutica de Juno	Pago por adelantado de $ 22 millones	2018
Bristol Myers Squibb	Pago por adelantado de $ 30 millones	2019

Plataformas de tecnología de licencia

Ingresos de licencia de la plataforma de genes CRISPR:

• Ingresos totales de licencia en 2022: $ 15.3 millones
• Ingresos totales de licencia en 2023: $ 12.7 millones

Financiación de la asociación estratégica

Pareja	Compromiso de financiación total	Enfoque de investigación
Vértices farmacéuticos	$ 90 millones	Anemia drepanocítica
Astrazeneca	$ 60 millones	Objetivos oncológicos

Financiación de subvenciones e investigación

• NIH subvenciones en 2022: $ 4.2 millones
• Financiación de la investigación de DARPA: $ 3.5 millones
• Total de investigación de la investigación 2023: $ 7.8 millones

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Value Propositions

You're looking at the core offering from Editas Medicine, Inc., and it centers on delivering potential one-time, durable genomic medicines for serious diseases. This focus on durability is key; think about replacing a chronic treatment regimen with a single intervention. The company's strategy, as of late 2025, heavily emphasizes in vivo gene editing, meaning the therapy is delivered directly into the body to make the edit, rather than removing cells, modifying them outside, and putting them back in (ex vivo).

The differentiation comes from the specific mechanism they are employing for certain targets, like the upregulation strategy. This approach aims to increase the expression of a target protein rather than just fixing a broken one. For their lead candidate, EDIT-401, this means driving up the production of the LDL receptor (LDLR) protein. This strategy is supported by preclinical results showing that only a moderate level of functional editing of LDLR alleles, around 10-40% in the liver, can achieve a massive functional benefit.

The preclinical data for EDIT-401, targeting high LDL cholesterol, is what really anchors this value proposition right now. The numbers from non-human primate (NHP) studies are compelling, showing a rapid and profound effect after just a single dose. Here's the quick math on that proof-of-concept:

Metric	Result in NHPs (Single Dose)
Mean LDL-C Reduction	≥90%
Time to Effect	Within 48 hours
Mean LDLR Protein Increase	≥6-fold
Durability in Mice	Maintained over three months

This in vivo approach is inherently less invasive than the ex vivo cell therapy route, which often requires complex procedures like chemotherapy conditioning and stem cell transplantation. Editas Medicine's strategic shift is evident in their financials; for example, research and development expenses for the three months ended September 30, 2025, decreased by $27.9 million compared to the same period in 2024, partly due to discontinuing the reni-cel program, which was an ex vivo cell medicine. The company is clearly prioritizing the in vivo platform, which they plan to advance with an Investigational New Drug (IND) submission for EDIT-401 by mid-2026, aiming for initial human proof-of-concept data by the end of 2026. Financially, they are positioned to support this focus, with an extended cash runway into the third quarter of 2027, even while reporting a net loss of $25.1 million for Q3 2025, which was an improvement from the $62.1 million loss in Q3 2024. Also, collaboration revenues, like the $7.5 million recognized in Q3 2025 from the BMS agreement, help fund this focused development.

The core benefits you get from this strategy include:

• Potential for a one-time treatment for serious, chronic conditions.
• Delivery via intravenous administration using proprietary targeted lipid nanoparticles (tLNP).
• Focus on upregulation, which can be more potent than simple gene correction.
• Reduced procedural burden compared to ex vivo approaches.

Finance: draft 13-week cash view by Friday.

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Customer Relationships

You're managing relationships in the high-stakes world of gene editing, where strategic alliances and clear scientific communication are everything. For Editas Medicine, Inc., the customer relationship structure is heavily weighted toward sophisticated partners and the broader scientific/investor community.

High-touch, strategic management of large pharma collaborations (BMS)

The relationship with Bristol Myers Squibb (BMS) is definitely a cornerstone of the partnership strategy. This is a high-touch management exercise because the deliverables are complex, involving gene-edited T-cell therapies. The depth of this relationship is shown by the sheer volume of programs involved.

Here's a quick look at the scale of the Bristol Myers Squibb relationship as of late 2025:

Collaboration Metric	Value/Status
Programs Opted Into (Total)	13
Gene Targets Covered	11
Programs in IND-Enabling Studies (Q2 2025)	2
Programs in Late-Stage Discovery (Q2 2025)	4
IND/CTA Acceptance (CD19 HD Allo CAR T)	Triggered Milestone Payment in Q2 2025
Collaboration Extension End Date	2026 (with options extending into 2028)

That first IND/CTA acceptance for the CD19 HD Allo CAR T program in Q2 2025 triggered a milestone payment, showing direct financial validation from the partner. Also, revenue recognition related to a milestone achieved under the BMS collaboration was reported in the third quarter of 2025.

Direct communication with investors via press releases and SEC filings

For investors, Editas Medicine, Inc. relies on structured, scheduled disclosures, having moved away from hosting quarterly conference calls. You get your primary updates through official filings and press releases.

Key communication touchpoints in 2025 included:

• Announcing Q3 2025 results on November 10, 2025, via press release and SEC filings.
• Reporting Q1 2025 results on May 12, 2025, through press release and SEC filings.
• The company's cash position as of September 30, 2025, stood at $165.6 million.
• The projected operational cash runway extends into the third quarter of 2027.
• SEC filings in 2025 included a 10-Q on Nov 10 and an 8-K on Oct 9.

The company is defintely using these formal channels to manage expectations about its financial health and pipeline progression.

Scientific engagement through conference presentations and publications

Scientific credibility is a critical relationship builder in this sector, proving the technology works outside the lab. Editas Medicine, Inc. actively engages the scientific community by presenting data at major industry meetings.

Recent scientific engagement included:

• Presenting preclinical data for EDIT-401 at the 32nd Annual European Society of Gene and Cell Therapy (ESGCT) Congress in October/November 2025.
• Presenting EDIT-401 data at the American Heart Association (AHA) Scientific Sessions 2025.
• Sharing in vivo preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting in May 2025.
• Presenting data at the TIDES USA 2025 conference in May 2025.
• Sharing new in vivo data in June 2025 at the European Hematology Association (EHA) 2025 Congress.

Looking ahead, management planned to participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, keeping the dialogue open with the investment community.

Finance: draft 13-week cash view by Friday.

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Channels

You're looking at how Editas Medicine, Inc. gets its science and corporate story out to the world, from potential pharma partners to the investors watching the ticker. It's a mix of formal scientific exchange and required financial disclosure.

Direct licensing and collaboration agreements with pharmaceutical partners

The channel for deep, long-term value creation is through these partnerships. Revenue recognition here is lumpy, tied to specific milestones being hit. For the three months ended September 30, 2025, Collaboration and other research and development revenues hit $7.5 million, a big jump from just $0.1 million for the same period in 2024. This Q3 2025 revenue spike was mainly due to a milestone achieved under the collaboration agreement with BMS.

The company's technology licensing is also a key channel, particularly the foundational IP. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. Monetizing this IP is active; for instance, Editas Medicine received an upfront cash payment of $57 million from DRI Healthcare Trust by selling certain future license fees related to the Vertex Pharmaceuticals Cas9 agreement. Those future fees range from $5 million to $40 million annually, plus a mid-double-digit percentage of a $50 million contingent upfront payment from Vertex.

Financial Metric/Agreement Detail	Value/Status as of Late 2025
Q3 2025 Collaboration Revenue	$7.5 million
Q3 2024 Collaboration Revenue	$0.1 million
Key Collaboration Partner Triggering Q3 2025 Revenue	BMS (Milestone achieved)
Upfront Payment from DRI for Vertex Fees Monetization	$57 million
Expected Annual License Fees from Vertex (Range)	$5 million to $40 million
Cash, Cash Equivalents, and Marketable Securities (Sep 30, 2025)	$165.6 million
Expected Cash Runway	Into the third quarter of 2027

Scientific conferences (ASGCT, AHA, ESGCT) for data dissemination

Disseminating preclinical data at major scientific venues validates the science. Editas Medicine presented preclinical data on its lead candidate, EDIT-401, at several key meetings in late 2025. The oral presentation at the 32nd Annual European Society of Gene and Cell Therapy (ESGCT) Congress (October 7-10, 2025) was led by the Executive Vice President and Chief Scientific Officer, Dr. Linda Burkly. The abstract number for that oral presentation was OR069.

Also, the company presented a moderated digital poster at the American Heart Association (AHA) Scientific Sessions 2025 (November 7-10, 2025). The data presented at both AHA and ESGCT demonstrated over 90% LDL-C reduction in non-human primates with EDIT-401. Earlier in the year, data was presented at the ASGCT annual meeting in May 2025.

Management also used investor conferences as a channel:

• H.C. Wainwright Genetic Medicines Virtual Conference: Fireside Chat on October 14, 2025.
• Chardan 9th Annual Genetic Medicines Conference: Panel Discussion on October 21, 2025.
• 8th Annual Evercore Healthcare Conference: Fireside Chat on December 2, 2025, at 9:10 AM EST.

Regulatory submissions (IND/CTA) to the FDA and other agencies

The path to the clinic is formalized through regulatory filings. Editas Medicine remains on track to submit an Investigational New Drug (IND) or Clinical Trial Application (CTA) for EDIT-401 by mid-2026. The goal is to achieve initial in vivo human proof-of-concept data by year-end 2026.

A key regulatory milestone was already achieved via a partner channel: the first IND/CTA was accepted for the CD19 HD Allo CAR T program, which is part of the collaboration with Bristol Myers Squibb. This acceptance triggered a milestone payment. The company also anticipated establishing one additional target cell type/tissue beyond HSCs and the liver by the end of 2025.

Investor Relations website for corporate and financial updates

The Investor Relations section of www.editasmedicine.com is the primary hub for financial transparency. The company announced its Third Quarter 2025 Results and Business Updates on November 10, 2025, via press release and SEC filings. Importantly, the company stated it does not plan to host quarterly financial results conference calls moving forward.

For public market data as of December 4, 2025, 3:50 PM EST:

Stock Metric	Value
NASDAQ Ticker	EDIT
Closing Price	$2.44
Volume	1,293,645
52 Week High	$4.54
52 Week Low	$0.91
Common Shares Outstanding (Oct 31, 2025)	97,618,660

Webcasts for investor presentations are available live, with archived replays remaining accessible for approximately 30 days following each event.

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Customer Segments

You're looking at the customer base for Editas Medicine, Inc. (EDIT) as of late 2025. This is a company deep in the R&D phase, so the 'customers' aren't buying pills yet; they are partners, patients waiting for breakthroughs, and the capital markets funding the journey. Honestly, the segments reflect this high-risk, high-reward biotech reality.

Large pharmaceutical and biotech companies seeking gene editing assets

This segment is crucial because, right now, their revenue is driven by strategic alliances, not product sales. These larger entities provide the capital and potential commercial scale that Editas Medicine, Inc. needs to advance its pipeline. You can see this dependency clearly in the Q3 2025 results, where Collaboration and other research and development revenues hit $7.5 million, a massive jump from the $0.1 million in the same period in 2024. That surge was tied to a milestone achieved under the collaboration agreement with Bristol Myers Squibb (BMS). Also, the company retains rights under a license agreement with Vertex Pharmaceuticals, which contributes to their extended cash runway. These companies are buying access to Editas Medicine, Inc.'s proprietary CRISPR/Cas12a and Cas9 patent estates for human medicines.

Patients with serious genetic diseases with high unmet need (e.g., high LDL-C)

For patients, the value proposition is a potential one-time, transformative therapy. The lead in vivo development candidate, EDIT-401, targets the reduction of LDL cholesterol (LDL-C). The preclinical data is compelling: it showed a mean LDL-C reduction of >90% in non-human primates, which is significantly better than the 40%-60% mean reduction seen with standard of care therapies. The near-term action for this segment is waiting; Editas Medicine, Inc. is on track to submit the Investigational New Drug (IND) or Clinical Trial Application (CTA) for EDIT-401 by mid-2026, aiming for initial human proof-of-concept data by year-end 2026.

Here's a quick look at the pipeline progress and financial backing supporting this patient focus:

Metric	Value / Date	Relevance
EDIT-401 NHP Efficacy	>90% mean LDL-C reduction	Potential superiority over standard of care (40%-60% reduction)
Cash Runway End Date	Third quarter of 2027	Funds operations through key data milestones
Cash, Cash Equivalents, Marketable Securities (as of 9/30/2025)	$165.6 million	Financial stability for R&D progression
Target IND/CTA Submission for EDIT-401	Mid-2026	Timeline to initiate human trials

Clinical investigators and research hospitals for trials

This group is essential for executing the clinical strategy, especially as Editas Medicine, Inc. pivots to in vivo therapies targeting the liver and hematopoietic stem cells (HSCs). While specific numbers of active trial sites aren't public, their engagement is evidenced by the scientific dissemination activities. For instance, preclinical data for EDIT-401 was presented at the American Heart Association (AHA) Scientific Sessions 2025 and the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress. These presentations are how Editas Medicine, Inc. establishes credibility with the investigators who will eventually run their trials.

Institutional and individual investors in the biotech sector

Investors are buying into the potential of the CRISPR technology and the extended financial runway. As of October 31, 2025, the stock price was $3.08, with a market capitalization of $277M based on 97.6M shares outstanding. The ownership structure shows significant institutional interest; there are 327 institutional owners on file. For example, BlackRock, Inc. held 8,019,891 shares as of September 30, 2025. The market is clearly watching the burn rate; the net loss for Q3 2025 was $25.1 million, though this was narrower than the prior year's loss of $62.1 million. The company is actively managing capital, having raised $17.8 million in gross equity proceeds from its ATM facility during Q3 2025.

Investor sentiment is shaped by key financial and operational milestones:

• Stock price on December 3, 2025: $2.36
• Estimated total revenue for the full 2025 fiscal year: $12.67 million
• Number of institutional investors holding positions: 327
• Total Value of Holdings by major institutions (as of 9/30/2025): $105 million
• Net Loss for Q3 2025: $25.1 million

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Cost Structure

You're looking at the major drains on Editas Medicine, Inc.'s cash reserves as they push their in vivo pipeline forward. For a company like Editas Medicine, the Cost Structure is almost entirely driven by the science.

Dominantly Research and Development (R&D) expenses are the single largest cost component. This covers everything from lab work and discovery to preclinical studies and manufacturing scale-up for their gene editing candidates. The focus has clearly shifted following the discontinuation of the reni-cel program.

The R&D spend shows a significant reduction compared to the prior year, reflecting that strategic pivot. For the third quarter ending September 30, 2025, Research and Development expenses were reported at $19.8 million. That's a sharp drop when you compare it to the $47.6 million incurred in the third quarter of 2024. To give you a broader view of the year-to-date trend, the first quarter of 2025 saw R&D expenses of $26.6 million, down from $48.8 million in Q1 2024.

The cost structure was heavily impacted by one-time charges early in the year. The first quarter of 2025 included significant restructuring and impairment charges totaling $40.9 million. These charges were tied directly to the discontinuation of the reni-cel program, covering workforce reductions and impairment of related equipment. For the nine months ended September 30, 2025, the cumulative restructuring and impairment charges amounted to $66.9 million. To be fair, Editas Medicine did not recognize any restructuring and impairment charges in the third quarter of 2025 itself.

Here's a quick look at the operating expense shift:

• Q3 2025 R&D: $19.8 million
• Q3 2024 R&D: $47.6 million
• Q3 2025 G&A: $12.3 million
• Q3 2024 G&A: $18.1 million

General and administrative costs, which cover corporate overhead, executive salaries, and non-R&D related support functions, also saw a reduction as headcount was streamlined. General and administrative expenses for Q3 2025 were $12.3 million, down from $18.1 million in Q3 2024. This reflects the reduced workforce following the December 2024 program discontinuation.

The final major cost category involves Intellectual property maintenance and licensing fees. Editas Medicine is the exclusive licensee for key CRISPR patent estates from the Broad Institute and Harvard University for human medicines. This means they incur ongoing costs to maintain these licenses, including potential milestone payments, success fees, royalty fees, and patent maintenance costs owed to licensors. While the exact recurring expense for these fees in 2025 isn't itemized separately in the high-level releases, these obligations are contingent upon future development and regulatory success.

You can see the material impact of the strategic shift on operating expenses in this comparison:

Expense Category	Period	Amount (USD)
Restructuring and Impairment Charges	Q1 2025 (Three Months)	$40.9 million
Restructuring and Impairment Charges	Nine Months Ended Sept 30, 2025 (YTD)	$66.9 million
Research and Development Expenses	Q3 2025 (Three Months)	$19.8 million
General and Administrative Expenses	Q3 2025 (Three Months)	$12.3 million

Finance: draft 13-week cash view by Friday.

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Revenue Streams

You're looking at how Editas Medicine, Inc. funds its operations right now, and honestly, it's all about partnerships and hitting specific targets. For a company deep in the R&D phase, revenue isn't coming from selling a commercial product; it's coming from the value embedded in its intellectual property and the success of its collaborators.

The primary source of top-line income is clearly tied to external agreements. For the third quarter ending September 30, 2025, Collaboration and other R&D revenues hit $7.54 million. That number is a huge jump compared to the $0.1 million recognized in the same period of 2024, showing the lumpy, milestone-driven nature of this income.

Here's a quick look at how that Q3 revenue stacks up against the analyst view for the full year:

Metric	Amount
Q3 2025 Collaboration & R&D Revenue	$7.54 million
Analyst-Estimated Full-Year 2025 Revenue	$12.67 million
Q3 2024 Collaboration & R&D Revenue	$0.1 million

What this estimate hides is that the full-year number relies heavily on hitting future milestones, which is standard for this sector. If onboarding takes longer than expected, that full-year projection could shift.

The key drivers for these revenue events are structured around the value of Editas Medicine's gene editing platform:

• Collaboration and other R&D revenues (Q3 2025: $7.54 million).
• Milestone payments from strategic partners, such as the recognition tied to the Bristol Myers Squibb (BMS) collaboration, specifically following an Investigational New Drug (IND) application acceptance for their CD19 HD Allo CAR T program.
• Licensing and sublicensing revenue from foundational CRISPR IP, evidenced by retained payments under the license agreement with Vertex Pharmaceuticals, which contributes to extending the cash runway.

To be fair, the Q3 surge was almost entirely due to one significant event. The increase was primarily attributable to the recognition of revenue related to a milestone achieved under the Company's collaboration agreement with BMS in the third quarter of 2025. This underscores that revenue visibility is low until a specific development or regulatory event occurs.

Finance: draft 13-week cash view by Friday.